Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Multicenter, Open-label Phase III Study to Evaluate the Efficacy and Safety of Adding Metronomic Chemotherapy of Capecitabine to Standard Adjuvant Therapy for Patients With High Risk HER2-positive Primary Breast Cancer

Trial Profile

A Randomized, Multicenter, Open-label Phase III Study to Evaluate the Efficacy and Safety of Adding Metronomic Chemotherapy of Capecitabine to Standard Adjuvant Therapy for Patients With High Risk HER2-positive Primary Breast Cancer

Recruiting
Phase of Trial: Phase III

Latest Information Update: 03 Aug 2018

At a glance

  • Drugs Capecitabine (Primary)
  • Indications Early breast cancer; Male breast cancer
  • Focus Therapeutic Use
  • Acronyms SMART
  • Most Recent Events

    • 25 Jul 2018 Planned number of patients changed from 840 to 794.
    • 25 Jul 2018 Status changed from not yet recruiting to recruiting.
    • 27 Jun 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top